1.
Toble N,
Detmar M.
Tumor and lymph node lymphangiogenesis-impact on cancer metastasis.
J Leukoc Biol.
2006;80:691-6.
2.
Kosuçu P,
et al.
Mediastinal lymph nodes: assessment with diffusion-weighted MR imaging.
J Magn Reson Imaging.
2009;30:292-7.
3.
Morton DL,
et al.
Technical details of intraoperative lymphatic mapping for early stage melanoma.
Arch Surg.
1992;127:392-9.
4.
Haberkorn U,
et al.
FDG uptake,
tumor proliferation and expression of glycolysis associated genes in animal tumor models.
Nucl Med Biol.
1994;21:827-34.
5.
Kubota R,
et al.
Intratumoral distribution of fl uorine-18-fl uorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.
J Nucl Med.
1992;33:1972-80.
6.
Hunt BM,
et al.
Sarcoidosis as a benign cause of lymphadenopathy in cancer patients.
Am J Surg.
2009;197:629-32.
7.
Elstrom RL,
et al.
Combined PET and low-dose,
non contrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.
Ann Oncol.
2008;19:1770-3.
8.
Lardinois D,
et al.
Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.
N Engl J Med.
2003;348:2500-7.
9.
Silvestri GA,
et al.AmericanCollegeof Chest Physicians.
Non invasive staging of non-small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
Chest.
2007;132:178S-201.
10.
Lu YY,
et al.
A systematic review and meta-analysis of pre-therapeutic lymph node staging of colorectal cancer by 18F-FDG PET or PET/CT.
Nucl Med Commun.
2012;33:1127-33.
11.
El-Maraghi RH,
Kielar AZ.
PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention,
comparison,
outcome analysis.
J Am Coll Radiol.
2008;5:924-31.
12.
Pichio M,
et al.
Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings.
J Nucl Med.
2006;47:938-44.
13.
Liao LJ,
et al.
Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck-a meta- analysis comparing different imaging modalities.
BMC Cancer.
2012;12:236.
14.
Padhani AR,
et al.
Whole-body diffusion-weighted MR imaging in cancer: current status and research directions.
Radiology.
2011;261:700-18.
15.
Park SO,
et al.
Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer.
J Magn Reson Imaging.
2009;29:383-90.
16.
Herneth AM,
et al.
Diffusion weighted imaging: lymph nodes.
Eur J Radiol.
2010;76:398-405.
17.
Vandecaveye V,
et al.
Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging.
Radiology.
2009;251:134-44.
18.
Maeda M,
et al.
Usefulness of the apparent diffusion coefficient in line scan diffusion-weighted imaging for distinguishing between squamous cell carcinomas and malignant lymphomas of the head and neck.
Am J Neurorad.
2005;26:1186-92.
19.
Chen W,
et al.
Whole-body diffusion-weighted imaging vs.
FDG-PET for the detection of nonsmall-cell lung cancer.
How do they measure up? Magn Reson Imaging.
2010;28:613-20.
20.
Wu LM,
et al.
Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better? J Surg Res.
2012;178:304-14.
21.
Park SO,
et al.
Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer.
J Magn Reson Imaging.
2009;29:383-90.
22.
Chen YB,
et al.
Discrimination of metastatic from hyperplastic pelvic lymph nodes in patients with cervical cancer by diffusion-weighted magnetic resonance imaging.
Abdom Imaging.
2011;36:102-9.
23.
Eiber M,
et al.
Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging.
Invest Radiol.
2010;45:15-23.
24.
Hamstra DA,
et al.
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck.
Transl Oncol.
2008;1:187-94.
25.
Zima A,
et al.
Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? Am J Neurorad.
2007;28:328-34.
26.
Sauter AW,
et al.
Source correlation between [(18)F] FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-smallcell lung cancer.
Eur J Nucl Med Mol Imaging.
2013;40:677-84.
27.
Chawla S,
et al.
Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck.
AJR Am J Roentgenol.
2013;200:35-43.
28.
Lu Q,
et al.
Chronic lower extremity lymphedema: a comparative study of high-resolution interstitial MR lymphangiography and heavily T2-weighted MRI.
Eur J Radiol.
2010;73:365-73.
29.
Saksena MA,
et al.
Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
Eur J Radiol.
2006;58:367-74.
30.
Thoeny HC,
et al.
Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients.
Eur Urol.
2009;55:761-9.
31.
Alam F,
et al.
Accuracy of sonographic elastography in the differential diagnosis of enlarged cervical lymph nodes: comparison with conventional B-mode sonography.
AJR Am J Roentgenol.
2008;191:604-10.
32.
Taylor K,
et al.
Ultrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: a pilot study.
Clin Radiol.
2011;66:1064-71.
33.
Lyshchik A,
et al.
Cervical lymph node metastases: diagnosis at sonoelastography initial experience.
Radiology.
2007;243:258-67.
34.
Ying M,
et al.
Accuracy of sonographic vascular features in differentiating causes of cervical lymphadenopathy.
Ultrasound Med Biol.
2004;30:441-7.